184 related articles for article (PubMed ID: 33313223)
1. Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma.
Ma K; Qiao Y; Wang H; Wang S
Ann Transl Med; 2020 Nov; 8(22):1478. PubMed ID: 33313223
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
[TBL] [Abstract][Full Text] [Related]
3. Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells.
Tong L; Shan M; Zou W; Liu X; Felsher DW; Wang J
Front Oncol; 2022; 12():904969. PubMed ID: 35978822
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Wang D; Li Y; Chen X; Li P
Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
Sepesi B; Nelson DB; Mitchell KG; Gibbons DL; Heymach JV; Vaporciyan AA; Swisher SG; Roszik J
Ann Thorac Surg; 2018 Jun; 105(6):1621-1626. PubMed ID: 29510096
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of the immune microenvironment associated with RRM2 expression and its application to PD-L1/PD-1 inhibitors in lung adenocarcinoma.
Lee SK; Hwang Y; Han JH; Haam S; Lee HW; Koh YW
Am J Cancer Res; 2023; 13(11):5443-5454. PubMed ID: 38058821
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
8. Relationship between PD-L1 expression and molecular aberrances in lung adenocarcinoma with solid components.
Zhu K; Zou Y; Zhao L; Tao Y; Lu S; Hou Y; Chen G
J Thorac Dis; 2023 Jun; 15(6):2936-2947. PubMed ID: 37426139
[TBL] [Abstract][Full Text] [Related]
9. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
[TBL] [Abstract][Full Text] [Related]
10. Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma.
Leng X; Wei S; Mei J; Deng S; Yang Z; Liu Z; Guo C; Deng Y; Xia L; Cheng J; Zhao K; Gan F; Li C; Merrell KW; Molina JR; Metro G; Liu L
Transl Lung Cancer Res; 2021 Feb; 10(2):965-980. PubMed ID: 33718036
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
[TBL] [Abstract][Full Text] [Related]
12. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
Yang P; He S; Ye L; Weng H
Int Arch Allergy Immunol; 2024 May; ():1-11. PubMed ID: 38781935
[TBL] [Abstract][Full Text] [Related]
13. Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis.
Hu ZY; Huang WY; Zhang L; Huang B; Chen SC; Li XL
Ann Transl Med; 2020 Sep; 8(18):1172. PubMed ID: 33241021
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression and CD8
Wang Y; Zhu C; Song W; Li J; Zhao G; Cao H
J Immunol Res; 2018; 2018():4180517. PubMed ID: 30003113
[TBL] [Abstract][Full Text] [Related]
15. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
17. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
18. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
19. Screening and validation of plasma cell-derived, purinergic, and calcium signalling-related genetic signature to predict prognosis and PD-L1/PD-1 blockade responses in lung adenocarcinoma.
Huang J; Fan X; Hu B; Chen L
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12931-12945. PubMed ID: 37468608
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer.
Chen S; Zhang N; Shao J; Wang T; Wang X
J Cancer; 2019; 10(3):697-707. PubMed ID: 30719168
[No Abstract] [Full Text] [Related]
[Next] [New Search]